Navigation Links
Veeva Systems Announces Dramatic Growth in Europe
Date:5/15/2012

BARCELONA, Spain and PHILADELPHIA, May 15, 2012 /PRNewswire/ --

Cloud-based Veeva CRM Now Deployed in Over 20 European Countries

With its 4th Annual Global Customer Summit kicking off this morning in Philadelphia, Veeva Systems announced dramatic growth of cloud-based Veeva CRM throughout the continent. Since Veeva's official expansion into Europe in April 2010, the company has delivered the advantages of cloud computing to more than 35 life sciences companies across 20+ different European markets. When all current deployments are complete, there will be over 30,000 European pharmaceutical representatives using Veeva CRM to better manage their relationships with customers. To support its large user base, Veeva has opened major offices in Barcelona, Budapest and Paris and, along with a network of strategic partners, currently has more than 200 certified Veeva Administrators to implement and support the cloud-based CRM solution in Europe.

     (Logo: http://photos.prnewswire.com/prnh/20120425/527164)

Veeva's European customers include dozens of emerging biotechs and specialty companies as well as ten of the Top 20 global pharmaceutical companies. Key global customers include Astellas Pharma, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, and Novartis; key specialty leaders include Actelion, Grünenthal, LEO Pharma, and Stallergenes; and small and medium-sized customers include Human Genome Sciences, Iroko Cardio, Mundipharma, and Pharco Pharma.

"Winning in today's challenging European pharmaceutical environment requires a fundamentally different commercial approach. To support our new commercial model, we wanted a CRM solution that was truly pan-European, future-proof and agile enough to grow with our organisational needs. Veeva CRM was the only solution to meet all these business requirements," said Wim Kockelkoren, senior vice president EMEA Commercial Effectiveness and CEE Region, Aste
'/>"/>

SOURCE Veeva Systems
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Stallergenes Moves to the Cloud With Veeva CRM
2. Pharco Pharma NV/SA Leverages Advantages of Cloud Computing With the Implementation of Veeva CRM
3. Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements
4. New Forecast Shows Patient Monitoring Systems Market to Reach $18.9 billion by 2016
5. Middle East and Africa Endoscopy Devices Market Outlook to 2017 - Flexible Endoscopes, Rigid Endoscopes, Endoscopy Visualization Systems, Capsule Endoscope Systems and Others
6. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
7. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
8. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
9. Delcath Systems, Inc. Secures $20 Million Credit Facility
10. GeckoSystems Evaluates Europes Robotic Wheelchair Market
11. PLC Systems RenalGuard to be Demonstrated at Cardiology Meetings in Germany and Israel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
(Date:7/10/2014)... Calif. , July 10, 2014 Integrated ... leader in advanced memory and analog IC solutions, today ... on Thursday, July 24, 2014, at 7:00 a.m. Pacific ... financial results for the fiscal 2014 third quarter ended ... call via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific ...
(Date:7/10/2014)... Quebec , July 10, 2014  Valeant Pharmaceuticals ... VRX) today announced it has completed the sale to ... and Dysport owned or held by Valeant for $1.4 ... with Nestle S.A, which recently completed its acquisition of ... the divestiture of our products to a company that ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... ActivBiotics, Inc. today,announced the results of its ... rifalazil in the treatment of intermittent claudication,associated ... demonstrated,that treatment for two months with the ... significant improvement in walking distance,claudication onset times, ...
... Scientific Sessions ... 2007 in Orlando, Florida, ... ) today announced the successful completion,of its Phase 2b trial ... vaccine being,developed to treat nicotine addiction and prevent smoking relapse. ...
Cached Medicine Technology:Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 2Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 2Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 4Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 5Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 6Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 7
(Date:7/13/2014)... Recently, iFitDress.com, one of the most famous dress ... of brown evening dresses for worldwide clients. ... discounted prices, up to 50% off. , All ... are carefully made according to most fashionable styles. In ... offers pretty accessories: wedding shoes, dancing shoes, sandals, boots ...
(Date:7/13/2014)... a professional supplier of funeral products. According to the company’s ... the global market. Recently, the company has announced its latest ... offer for all the newly released items. , Despite ... made with superb materials. As is commonly noted, a nice ... the departed saint. MillionaireCasket.com is always here to help. , ...
(Date:7/13/2014)... the best treatment and variations in the quality of ... blood cancer patients still varies widely between regions within ... in European adults to date, published in The ... 5-year survival for most cancers of the blood has ... the approval of new targeted drugs in the early ...
(Date:7/13/2014)... County, NC (PRWEB) July 13, 2014 ... of its newest location, the Carolinas HealthCare System - ... facility replaces the aged Anson Community Hospital in Wadesboro. ... is approximately three miles from the previous facility. Situated ... single-story floorplan that includes an emergency room drop-off, helipad, ...
(Date:7/13/2014)... Nature Genetics identifies a novel genetic and ... esophagitis (EoE), opening up potential new therapeutic strategies ... , EoE is a chronic inflammatory disorder of ... hypersensitivity to certain foods and an over-accumulation in ... (part of the body,s immune system). EoE can ...
Breaking Medicine News(10 mins):Health News:2014 Brown Evening Dresses Added To iFitDress.com 2Health News:Brand New Cherry Caskets Unveiled By China Casket Supplier MillionaireCasket.com 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3
... Asia are born and die without leaving a trace ... information on which to base public health decisions, a ... colleagues say in a paper published today (Oct. 29, ... However, affordable solutions exist to collect these vital statistics ...
... Treatment Times, Optimize Planning, Objectives and Offer Increased ... Oct. 29 Accuray,Incorporated (Nasdaq: ARAY ), ... today four new products designed to improve treatment ... in radiation delivery. These products are being launched ...
... Ongoing Oncology Program for MDX-1106, PRINCETON, N.J., ... Inc. (Nasdaq: MEDX ) announced today the ... with the U.S. Food &,Drug Administration (FDA) for ... a fully human anti-PD-1 antibody being,investigated for the ...
... SAN DIEGO, Oct. 29 Arena Pharmaceuticals,Inc. (Nasdaq: ... to,present at the BIOCOM Investor Conference on November 2, ... at the Marriott Del Mar Hotel in San,Diego, California. ... to provide a corporate overview of the company and,its ...
... Office of Technology and Intellectual Property, has received a ... Society of U.S.A. and Canada. , The award stems ... University of Chicago and the Mayo Clinic. The deal ... risk of side effects from a standard first-line treatment ...
... S.C., Oct. 29 The federal government has,approved ... Medicare,Advantage and Medicare Part D product offerings. Enrollment ... BlueCross, products include two PPO plans, Medicare Blue(SM) ... Blue(SM),Private; and two prescription drug plans, MedBlue(SM) Rx ...
Cached Medicine News:Health News:Scandal of invisibility plagues countries with no civil registries 2Health News:Scandal of invisibility plagues countries with no civil registries 3Health News:Accuray Announces Four New Products at Nation's Leading Radiation Oncology Meeting 2Health News:Accuray Announces Four New Products at Nation's Leading Radiation Oncology Meeting 3Health News:Accuray Announces Four New Products at Nation's Leading Radiation Oncology Meeting 4Health News:Accuray Announces Four New Products at Nation's Leading Radiation Oncology Meeting 5Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 2Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 3Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 4Health News:Arena Pharmaceuticals to Present at the BIOCOM Investor Conference 2Health News:Arena Pharmaceuticals to Present at the BIOCOM Investor Conference 3Health News:Gene screen patent leads to 'Deal of Distinction' 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens...
Medicine Products: